00:00
05:26
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer. read more read less

10 years ago #2012, #advanced, #cancer, #cancergrace, #grace, #gracecast, #highlights, #hospital, #in, #inhibitor, #kras, #lung, #margaret, #mutation, #natasha, #nsclc, #of, #princess, #toronto, #university